These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 16476116)

  • 21. Optimal dose and target trough level in cyclosporine and tacrolimus conversion in renal transplantation as evaluated by lymphocyte drug sensitivity and pharmacokinetic parameters.
    Takeuchi H; Okuyama K; Konno O; Jojima Y; Akashi I; Nakamura Y; Iwamoto H; Hama K; Iwahori T; Uchiyama M; Ashizawa T; Matsuno N; Nagao T; Hirano T; Oka K
    Transplant Proc; 2005 May; 37(4):1745-7. PubMed ID: 15919452
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term evaluation of cyclosporine and tacrolimus based immunosuppression in pediatric liver transplantation.
    Hasenbein W; Albani J; Englert C; Spehr A; Grabhorn E; Kemper MJ; Burdelski M; Ganschow R
    Pediatr Transplant; 2006 Dec; 10(8):938-42. PubMed ID: 17096762
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of appropriate blood level in continuous intravenous infusion from trough concentrations after oral administration based on area under trough level in tacrolimus and cyclosporine therapy.
    Nakamura Y; Takeuchi H; Okuyama K; Akashi T; Jojima Y; Konno O; Akashi I; Hama K; Iwahori T; Ashizawa T; Hirano T; Oka K; Matsuno N; Nagao T
    Transplant Proc; 2005 May; 37(4):1725-7. PubMed ID: 15919445
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus.
    Levy G; Grazi GL; Sanjuan F; Wu Y; Mühlbacher F; Samuel D; Friman S; Jones R; Cantisani G; Villamil F; Cillo U; Clavien PA; Klintmalm G; Otto G; Pollard S; McCormick PA
    Liver Transpl; 2006 Oct; 12(10):1464-72. PubMed ID: 17004259
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of changing immunosuppressive monotherapy from Cyclosporin A to Tacrolimus in long-term, stable liver transplant recipients.
    Ott R; Bussenius-Kammerer M; Reck T; Koch CA; Kissler H; Hohenberger W; Müller V
    Transpl Int; 2004 Jan; 17(1):39-43. PubMed ID: 14504723
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Once-daily tacrolimus extended release formulation: experience at 2 years postconversion from a Prograf-based regimen in stable liver transplant recipients.
    Florman S; Alloway R; Kalayoglu M; Punch J; Bak T; Melancon J; Klintmalm G; Busque S; Charlton M; Lake J; Dhadda S; Wisemandle K; Wirth M; Fitzsimmons W; Holman J; First MR
    Transplantation; 2007 Jun; 83(12):1639-42. PubMed ID: 17589349
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evidence of different pharmacokinetics between cyclosporine and tacrolimus in renal transplant recipients: why cyclosporine is monitored by C2 level and tacrolimus by trough level.
    Takeuchi H; Matsuno N; Hirano T; Toraishi T; Konno O; Nakamura Y; Iwamoto H; Hama K; Unezaki S; Nagao T
    Transplant Proc; 2008 Sep; 40(7):2240-2. PubMed ID: 18790203
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Circadian and time-dependent variability in tacrolimus pharmacokinetics.
    Park SI; Felipe CR; Pinheiro-Machado PG; Garcia R; Tedesco-Silva H; Medina-Pestana JO
    Fundam Clin Pharmacol; 2007 Apr; 21(2):191-7. PubMed ID: 17391292
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An objective measure to identify pediatric liver transplant recipients at risk for late allograft rejection related to non-adherence.
    Venkat VL; Nick TG; Wang Y; Bucuvalas JC
    Pediatr Transplant; 2008 Feb; 12(1):67-72. PubMed ID: 18186891
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients.
    Fukudo M; Yano I; Yoshimura A; Masuda S; Uesugi M; Hosohata K; Katsura T; Ogura Y; Oike F; Takada Y; Uemoto S; Inui K
    Pharmacogenet Genomics; 2008 May; 18(5):413-23. PubMed ID: 18408564
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of long-term tacrolimus immunosuppression on renal function in liver transplant recipients.
    Corman SL; Coley KC; Schonder KS
    Pharmacotherapy; 2006 Oct; 26(10):1433-7. PubMed ID: 16999653
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Initial liver graft function is a reliable predictor of tacrolimus trough levels during the first post-transplant week.
    Lock JF; Malinowski M; Schwabauer E; Martus P; Pratschke J; Seehofer D; Puhl G; Neuhaus P; Stockmann M
    Clin Transplant; 2011; 25(3):436-43. PubMed ID: 20482563
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Can daclizumab reduce acute rejection and improve long-term renal function in tacrolimus-based primary renal transplant recipients?
    Cheung CY; Liu YL; Wong KM; Chan HW; Chan YH; Wong HS; Chak WL; Choi KS; Chau KF; Shek CC; Li CS
    Nephrology (Carlton); 2008 Jun; 13(3):251-5. PubMed ID: 18221256
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical outcomes of renal transplantation using liquid chromatographic monitoring of tacrolimus.
    Borrows R; Chusney G; Loucaidou M; James A; Stichbury J; Van Tromp J; Cairns T; Griffith M; Hakim N; McLean A; Palmer A; Papalois V; Taube D
    Ther Drug Monit; 2006 Apr; 28(2):269-73. PubMed ID: 16628143
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modified-release tacrolimus.
    Chisholm MA; Middleton MD
    Ann Pharmacother; 2006 Feb; 40(2):270-5. PubMed ID: 16449540
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetic interaction between tacrolimus and diltiazem: dose-response relationship in kidney and liver transplant recipients.
    Jones TE; Morris RG
    Clin Pharmacokinet; 2002; 41(5):381-8. PubMed ID: 12036394
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sirolimus-based immunosuppressive therapy in liver transplant recipient with tacrolimus-related chronic renal insufficiency.
    Yang YJ; Chen DZ; Li LX; Kou JT; Lang R; Jin ZK; Han DD; He Q
    Transplant Proc; 2008 Jun; 40(5):1541-4. PubMed ID: 18589147
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic drug monitoring of tacrolimus: a moving matter.
    Manzanares C
    Therapie; 2002; 57(2):133-6. PubMed ID: 12185961
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation.
    Staatz CE; Tett SE
    Clin Pharmacokinet; 2004; 43(10):623-53. PubMed ID: 15244495
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.